KIT and chronic myelogenous leukemia, BCR-ABL1 positive: Another study of CML with an Adar1 mutant mouse model found that ADAR1 deletion reversed leukocytosis and preferentially-depleted primitive Lin-Sca+Kit+ (LSK) leukemic cells [133], which would imply that ADAR1 should become a new molecular target for CML-directed therapeutics.